{"disease":{"id":"concurrent-chemoradiotherapy","name":"concurrent chemoradiotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06734702","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06288373","title":"Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05325554","title":"Multi-mode Rehabilitation of Abdominal Tumor Patients Undergoing Concurrent Chemoradiotherapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT07086456","title":"Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03963882","title":"NAC Followed by RH for the Treatment of LACC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT06342167","title":"Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03579004","title":"Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":48,"lead_sponsor_name":"Mona Frolova","has_results":false},{"nct_id":"NCT05772377","title":"Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05944809","title":"The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"JIANYANG WANG","has_results":false},{"nct_id":"NCT06378840","title":"the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06391190","title":"Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"RenJi Hospital","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}